triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE

Exclusion Criteria

• •Patients already treated with HIS+Ezetimibe on admission for the ACS event,
• •Patients currently, previously or planned to be treated with PCSK9i or inclisiran,
• •Patients treated currently or in the last 3 months with bempedoic acid or in whom this treatment is planned in the following 8 weeks,
• •Known allergy, sensitivity or intolerance to bempedoic acid and/or study drugs' formulation ingredients (e.g. lactose intolerance),
• •Patients with history of documented intolerance to statins, ezetimibe or bempedoic acid
• •Patients with known Familial Hypercholesterolemia (FH; heterozygous or homozygous),
• •Patients with plasma triglycerides concentration exceeding 400 mg/dL (4.52 mmol/L),
• •Patients with dysbetalipoproteinemia (type III hyperlipoproteinemia),
• •Unstable clinical status (hemodynamic or electrical instability),
• •Severe renal dysfunction (eGFR \<30 ml/min/1.73m2 using the CKD-EPI formula),
• •Active liver disease or hepatic dysfunction (AST or ALT levels \> 3xUNL),
• •Current enrolment in another investigational device or drug study,
• •Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception,
• •Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.